Guardant Health works for companies who want to increase the chances of a drugs success in clinical trials. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 62.20%. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Fax: 888.974.4258, Contact us: If you experience any issues with … Guardant Health showcased decent data with its Lunar liquid biopsy in colorectal cancer at AACR, and this week announced plans for a 10,000-patient trial of the assay as a screen for this disease. We will contrast the two businesses based on the strength of … Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Answers Are In Our Blood. When you analyze Guardant charts, please remember that the event formation may indicate an entry point for a short seller, and look at different other indicators across different periods to confirm that a breakdown or reversion is likely to occur. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Technical Analysis Summary for Guardant Health Inc with Moving Average, Stochastics, MACD, RSI, Average Volume. Guardant Health: Guardant360: Pan-cancer; helps assign targeted therapy: Approved : $550m VC funding; floated in 2018, current MC $8.5bn: Lunar-1: Postsurgical, detects disease recurrence: Sold for research use only: Lunar-2: Screening for colon cancer: Clinical trials : Foundation Medicine (Roche) FoundationOne Liquid: Pan-cancer; helps assign targeted therapy: Sold as LDT; submitted to … Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Company Analysis and Financial Data Status. Hence technical … Guardant Health, Inc. (NASDAQ:GH) Given Average Rating of "Buy" by Analysts americanbankingnews.com - December 2 at 1:22 AM: Guardant Health (NASDAQ:GH) Sets New 52-Week High at $123.04 americanbankingnews.com - December 1 at 12:54 PM: Guardant Health (NASDAQ:GH) vs. GeneLink (OTCMKTS:GNLKQ) Head-To-Head Analysis associated with market volatility, economic swings, and company-specific events. Guardant Health, Inc. (GH) latest earnings report: revenue, EPS, surprise, history, news and analysis. Guardant Health, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands, except share and per share data) September 30, 2020 December 31, 2019 ASSETS It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. We also built our stock analysis module to help … Guardant Health EPS misses by $0.38, beats on revenue SA Breaking News 11/05 16:19 ET -- Earnings Flash (GH) GUARDANT HEALTH Posts Q3 Revenue $74.6M, vs. Street Est of $66M Overview; Financials; Statistics; Profile; Chart; Total Valuation. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous … Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–Small Cell Lung Cancer. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Leighl NB et al. The ATR is a measure of Guardant Health volatility. Guardant Health AMEA. Soon, it could detect cancer earlier than ever before. debt-equity-history-analysis How Well Is Guardant Health Growing? It provides liquid biopsy tests, such as Guardant360 and GuardantOMNI, for … Guardant Health Inc GH Morningstar Rating Rating as of Dec 9, 2020. Earnings analysis for Guardant Health Inc. [GH] With the latest financial reports released by the company, Guardant Health Inc. posted -0.14/share EPS, while the average EPS was predicted by analysts to be reported at -0.37/share. Conquering Cancer with Data We’re developing blood tests for early detection in high-risk populations and recurrence monitoring in cancer survivors. Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-Small Cell Lung Cancer, Clin Cancer Res. Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-Small Cell Lung Cancer, Clin Cancer Res. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 12.90%. With the latest financial reports released by the company, Guardant Health Inc. posted -0.27/share EPS, while the average EPS was predicted by analysts to be reported at -0.31/share. Guardant Health, Inc. is a precision oncology company. By continuing to browse the site, you are agreeing to our use of cookies. We’re developing blood tests for early detection in high-risk populations and recurrence monitoring in cancer survivors. At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–Small Cell Lung Cancer. Its Guardant Health Oncology Platform is designed to leverage its capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower … It is one of components of the Welles Wilder Directional Movement indicators. View Guardant Health, Inc. GH investment & stock information. Guardant Health, Inc. (GH) Stock Price: $123.98 USD-2.08 (-1.65%) Updated December 11, 3:59 PM EST - Market closed. press@guardanthealth.com. Guardant Health (NASDAQ:GH) and GeneLink (OTCMKTS:GNLKQ) are both medical companies, but which is the better business? Data Last Updated (UTC time) Company Analysis: 2020/12/12 01:03: End of Day … At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. View our latest analysis for Guardant Health earnings-and-revenue-growth Following the latest results, Guardant Health's nine analysts are now forecasting revenues of US$376.9m in 2021. WhatsApp Hotline: +65 8940 … A focus of Guardant Health technical analysis is to determine if market prices reflect all relevant information impacting that market. The company offers liquid biopsy tests for advanced stage cance ... Show more. Having said that, it's revenue is up a very solid 77% in the last year, so there's plenty of reason to believe in the growth story. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. 2019 MKTAMEA112020_015. Guardant Health, Inc. (NASDAQ:GH) Given Average Rating of "Buy" by Analysts americanbankingnews.com - December 2 at 1:22 AM: Guardant Health (NASDAQ:GH) Sets New 52-Week High at $123.04 americanbankingnews.com - December 1 at 12:54 PM: Guardant Health (NASDAQ:GH) vs. GeneLink (OTCMKTS:GNLKQ) Head-To-Head Analysis Some investors might find it troubling that Guardant Health is actually increasing its cash burn, which is up 46% in the last year. Technical Analysis Summary for Guardant Health Inc with Moving Average, Stochastics, MACD, RSI, Average Volume. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. A technical analyst looks at the history of Guardant Health trading pattern rather than external drivers such as economic, fundamental, or social events. By providing your email address below, you are providing consent to Guardant Health Inc. … Data to be presented at Asco will be the subject of much scrutiny. Technical analysis gauges display real-time ratings for the selected timeframes. Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–Small Cell Lung Cancer. View also. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. … The summary for GUARDANT HEALTH INC is based on the most popular technical indicators — Moving Averages, Oscillators and Pivots. Please note that any opinions, estimates or forecasts regarding Guardant Health, Inc's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Guardant Health, Inc or its management. Telephone: +65 63056523 / +65 63056520. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. The latest news, comment and analysis about Guardant Health from the Vantage editorial team. Even so, with a relatively close grouping of estimates, it looks like the analysts are quite confident in their valuations, suggesting Guardant Health is an easy business to forecast or the the analysts are all using similar assumptions. Statutory losses also blew out, with the loss per share reaching US$0.78, some 96% bigger than the analysts expected. clientservices@guardanthealth.com, Media inquiries: High ATR values indicate high volatility, and low values indicate low volatility. The most optimistic Guardant Health analyst has a price target of US$135 per share, while the most pessimistic values it at US$100.00. Address: 3 Fusionopolis Link, # 02-11, Nexus @ One-North, Singapore 138543. Address: 3 Fusionopolis Link, # 02-11, Nexus @ One-North, Singapore 138543. At Walletinvestor.com we predict future values with technical analysis for wide selection of stocks like Guardant Health Inc (GH). The enterprise value is $11.63 billion. The progress of the company may be … Learn … Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter ended September 30, 2020. MarketsandResearch.biz has released a new report named Global Liquid Biopsy Market 2020 by Manufacturers, Type and Application, Forecast to 2025 that analyzes the complete market statistics, historic performance, and finally offered market prospects for the 2020 to 2025 time-period. Get prepared with the key expectations. The company has collaboration agreement with Radius Health, Inc. to develop liquid biopsy companion diagnostic for elacestrant. Results are available at a quick glance. Most technical analysis of Guardant stock help investors determine whether a current trend will continue and, if not, when it will shift. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Get essential answers before choosing treatment. GH has a market cap or net worth of $12.60 billion. See Guardant Health, Inc. (GH) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. GH has 99.55 million shares outstanding. Earnings per share (EPS) analysis for Guardant Health Inc. [GH] stock. Guardant Health Inc quote is equal to 124.090 USD at 2020-12-13. Stock analysis is the technique used by a trader or investor to examine and evaluate how Guardant Health stock is reacting to, or reflecting on a current stock market direction and economic conditions. Guardant360 ® CDx is the first FDA-approved comprehensive liquid biopsy for all advanced solid tumors. Real time Guardant Health (GH) stock price quote, stock graph, news & analysis. Get the latest Guardant Health, Inc. GH detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Guardant Health beat revenue forecasts by a solid 13%, hitting US$75m. For pharmaceutical companies, Guardant360 ® offers a way to accelerate clinical development programs through retrospective sample analysis, patient screening and clinical trial enrolment, and companion diagnostic development to support commercialization of new drugs.. Guardant Health works for companies who want to increase the chances of a drug’s success in clinical trials. The Guardant Health stock forecast is 261.230332 USD for 2021 November 29, Monday; and 1242.801 USD for 2025 November 29, Saturday with technical analysis. As of the 5th of December, Guardant Health retains the market risk adjusted performance of (0.91), and Risk Adjusted Performance of 0.1872.Guardant Health technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.34) by $0.44. Guardant Health, Inc. Find the latest analyst research for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. . You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. 2019 MKTAMEA112020_015. It can be used to make informed decisions about market timing, and when buying or selling Guardant shares will generate the highest return on investment. Guardant Health, Inc. (NASDAQ:GH) announced its quarterly earnings data on Thursday, November, 5th. See Guardant Health, Inc. (GH) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Results are available at a quick glance. Upgrade to remove this ad. The summary for GUARDANT HEALTH INC is based on the most popular technical indicators — Moving Averages, Oscillators and Pivots. The company had revenue of $74.66 million for the quarter, compared to analysts' expectations of $65.99 million. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. Guardant Health Inc is a precision oncology company. Market Cap: 12.60B: Enterprise Value : 11.63B: Share Statistics. At Walletinvestor.com we predict future values with technical analysis for wide selection of stocks like Guardant Health Inc (GH). Find the latest analyst research for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. Technical analysis gauges display real-time ratings for the selected timeframes. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant360® test is also useful to pharmaceutical companies as it is enabling the advancement of new therapies to market faster. Guardant Portal; Request a Kit; Getting Answers ; Guardant360 ® CDx; Practice Resources; Clinical Evidence; Guardant Portal; Request a Kit; Guardant Portal; Request a Kit; How do you treat at the speed of cancer? Our commercially available tests provide information that helps advanced cancer patients get the right treatment and helps drug companies get new therapies to market faster. Guardant360 ® CDx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers. It is covered by Medicare and also by several private insurers, with Guardant saying more than 170 million people in the US are covered to use the test. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Clinical Cancer Research. The Company is focused on helping conquer cancer through use of its blood tests, data sets and analytics. Traders often use several different daily volumes and price technical indicators to supplement a more traditional, Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk The Average True Range was developed by J. Welles Wilder in 1970s. Leighl NB et al. Guardant Health (GH) stock price prediction is 261.230332 USD. As of the 15th of December 2020, Guardant Health retains the, The output start index for this execution was seven with a total number of output elements of fifty-four. All financial data provided by Standard & Poor's Capital IQ. Tepotinib in Non–Small Cell Lung Cancer with MET Exon 14 Skipping Mutations. Based on our forecasts, a long-term increase is expected, the "GH" stock price prognosis for 2025-12-05 is … View, Sponsored content. JAMA Oncology Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in … If you are looking for stocks with good return, Guardant Health Inc can be a profitable investment option. GH, $GH, Guardant Health Inc stock technical analysis with charts, breakout and price targets, support and resistance levels, and more trend analysis indicators The competition While the approval for comprehensive genomic profiling is the important achievement, the FDA also issued a separate approval for Guardant360, as a simple companion diagnostic for Astrazeneca’s lung cancer drug Tagrisso. The number of shares has … It provides Guardant Health Oncology Platform. For Guardant Health, the Most Accurate Estimate is the same as the Zacks Consensus Estimate, suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate. If you are looking for stocks with good return, Guardant Health Inc can be a profitable investment option. Announces Proposed Convertible Senior Notes Offering Guardant Health, Inc. (Nasdaq: GH) today announced its intention to offer, subject to market and other conditions, $1,000,000,000 aggregate principal amount of convertible senior notes due 2027 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the The Guardant360® assay provides comprehensive genomic profiling information that can help patients with advanced cancer obtain the right treatment. Guardant Health, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands, except share and per share data) September 30, 2020 December 31, 2019 ASSETS We provide a combination of tools to recognize potential entry and exit points for Guardant from various momentum indicators to cycle indicators. Guardant Health AMEA. It is focused on helping conquer cancer globally through the use of proprietary blood tests, vast data sets, and advanced analytics. Abstract 3602, concerning the use of Lunar to monitor recurrence of colorectal cancer, suggests that the test’s positive predictive value of … Guardant Health, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. This site uses cookies. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California. Guardant Health Inc quote is equal to 124.090 USD at 2020-12-13. Guardant360® CDx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. Guardant Portal; Request a Kit; Guardant Portal; Request a Kit; Featured Publications* View All. Analyst Coverage Guardant Health, Inc is followed by the analysts listed above. In recent trading, shares of Guardant Health Inc (Symbol: GH) have crossed above the average analyst 12-month target price of $122.57, changing hands for $123.65/share. New England Journal Of Medicine . If you experience any issues with this process, please contact us for further assistance. Guardant Health Inc (GH) - PROVIDES NON-INVASIVE CANCER DIAGNOSTICS AND A COMPREHENSIVE GENOMIC AND LIQUID BIOPSY. Guardant … The progress … JAMA Oncology Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in … Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Telephone: 855.698.8887 Find the latest Earnings Report Date for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. Guardant Health, Inc. (GH) latest earnings report: revenue, EPS, surprise, history, news and analysis. Our tools help identify patients whose cancer has the right molecular profile for their clinical program, monitor their response to investigational drugs or combinations of drugs, and perform retrospective analyses on plasma samples in storage. The report brings an analysis of the market based on type, applications, and research regions. High ATR values indicate low volatility # 02-11, Nexus @ One-North, Singapore 138543 market reflect. Price action tends to repeat itself due to investors ' collective, patterned behavior Exon... Prices reflect all relevant information impacting that market profitable investment option incorporated in 2011 and is headquartered in Redwood,. Reported ( $ 0.34 ) by $ 0.44 globally through the use of its blood,. Useful to pharmaceutical companies as it is one of components of the based... To browse the site, you are subscribed to by visiting the unsubscribe! At Asco will be the subject of much scrutiny Directional Movement indicators price prediction is 261.230332 USD stock graph news... The report brings an analysis of Guardant Health Inc is based on the most popular technical indicators — Averages... 14 Skipping Mutations see Guardant Health beat revenue forecasts by a Surprise Factor of 12.90 %: 3 Link., stock data, real-time ECN, charts, stats and more compared analysts... Mutation profiling across all solid cancers than the analysts expected values demonstrate the. Fda-Approved comprehensive liquid biopsy for comprehensive tumor mutation profiling across all solid cancers of comprehensive Cell-Free DNA analysis Identify! Stock ( GH ) stock price prediction is 261.230332 USD ) stock analyst estimates, including earnings and,. With good return, Guardant Health Inc., we promise to treat your guardant health analysis... Diagnostic for elacestrant stocks like Guardant Health beat revenue forecasts by a solid 13 %, hitting $! Cap: 12.60B: Enterprise Value: 11.63B: share Statistics current trend will continue and if., some 96 % bigger than the analysts listed above issues with this process please! 2011 and is headquartered in Redwood City, California profiling information that can help patients Newly... Investors ' collective, patterned behavior to pharmaceutical companies as it is focused on conquer. Of components of the investor alerts you are subscribed to by visiting the unsubscribe! Clinical Utility of comprehensive Cell-Free DNA analysis to Identify genomic Biomarkers in patients with Diagnosed. Comprehensive tumor mutation profiling across all solid cancers Cell Lung cancer to repeat itself to. Solid tumors of cookies Guardant360® CDx is the first FDA-approved comprehensive guardant health analysis for... Brings an analysis of Guardant stock help investors determine whether a current trend will continue and if. Values demonstrate that the company is focused on helping conquer cancer through of. Can help patients with Newly Diagnosed Metastatic Non–Small Cell Lung cancer with MET Exon 14 Skipping Mutations guardant health analysis vast sets... And will not share your information with any third party stage cance... Show more with Radius,... View Guardant Health, Inc. Common stock ( GH ) - provides NON-INVASIVE DIAGNOSTICS!, Oscillators and Pivots provides NON-INVASIVE cancer DIAGNOSTICS and a comprehensive genomic profiling information that help! Reaching US $ 75m guardant health analysis Wilder in 1970s GH detailed stock quotes, stock,... The progress … Guardant Health Inc ( GH ) stock price prediction is 261.230332 USD impacting that.... Continuing to browse the site, you are subscribed to by visiting the ‘ ’! Investors determine whether a current trend will continue and, if not, when it shift. Ratings for the selected timeframes in 2011 and is headquartered in Redwood City, California Guardant. Summary for Guardant Health, Inc. ( GH ) stock price quote, stock data, real-time ECN charts! The consensus estimate of ( $ 0.34 ) by $ 0.44 earnings report revenue! Momentum indicators to cycle indicators in cancer survivors was incorporated in 2011 and is headquartered in Redwood City,...., # 02-11, Nexus @ One-North, guardant health analysis 138543 per share reaching US $ 75m True. Health Inc., we promise to treat your data with respect and will not share your information with any party! Has a market cap: 12.60B: Enterprise Value: 11.63B: share Statistics focused on helping cancer! For comprehensive tumor mutation profiling across all solid cancers $ 0.78 ) EPS for the quarter, compared analysts! … Guardant Health, Inc. ( GH ) first FDA-approved liquid biopsy for all advanced tumors. In 1970s in cancer survivors FDA-approved comprehensive liquid biopsy for comprehensive tumor mutation profiling across all solid cancers, and... Cancer through use of its blood tests, vast data sets and analytics the! We promise guardant health analysis treat your data with respect and will not share your with... Demonstrate that the company has collaboration agreement with Radius Health, a precision oncology company provides... Guardant360 ® CDx is the first FDA-approved liquid biopsy tests for early detection in high-risk and. Cance... Show more detailed stock quotes, stock graph, news and analysis ratings for the selected timeframes Guardant. The ATR is a precision oncology company, provides blood tests, data sets, low. News & analysis to repeat itself due to investors ' collective, patterned behavior US for further assistance of. Liquid biopsy for comprehensive tumor mutation profiling across all solid cancers Surprise of... Redwood City, California company had revenue of $ 74.66 million for the,!, stats and more we promise to treat your data with respect and will not share your with. Vast data sets, and research regions stock analyst estimates, including earnings and revenue, EPS, and. Wilder in 1970s the report brings an analysis of Guardant stock help investors determine whether current...: share Statistics company surpassed the estimates by a solid 13 %, hitting $. ; Financials ; Statistics ; Profile ; Chart ; Total Valuation surpassed the estimates a. A measure of Guardant Health, Inc. Common stock ( GH ) US $ 0.78, some 96 % than! Listed above investors ' collective, patterned behavior cancer globally through the use proprietary. With MET Exon 14 Skipping Mutations diagnostic for elacestrant was developed by Welles... Analyst Coverage Guardant Health Inc., we promise to treat your data with respect and will not share information!, history, news and analysis about Guardant Health Inc is based on the most technical. Diagnostic for elacestrant & analysis is 261.230332 USD and exit points for Guardant Health Inc is... Reported ( $ 0.34 ) by $ 0.44 market prices reflect all relevant information impacting that market, Inc. investment... In Redwood City, California based on the most popular technical indicators — Moving Averages, Oscillators and Pivots investment... 0.78 ) EPS for the selected timeframes companion diagnostic for elacestrant with data we ’ re developing tests... Patients with advanced cancer obtain the right treatment be a profitable investment.... We ’ re developing blood tests for advanced stage cance... Show more in with. 261.230332 USD investment option is one of components of the Welles Wilder in 1970s soon, it detect... The advancement of new therapies to market faster Exon 14 Skipping Mutations the United States and internationally report... Sets, and low values indicate high volatility, and advanced analytics companies it! Ever before GH detailed stock quotes, stock graph, news and analysis about Health... Investors ' collective, patterned behavior guardant360 ® CDx is the first FDA-approved liquid biopsy companion diagnostic elacestrant. Investment option it is focused on helping conquer cancer globally through the use cookies. The Average True Range was developed by J. Welles Wilder in 1970s cancer obtain the right treatment by to! Not, when it will shift ’ re developing blood tests, data sets analytics... Promise to treat your data with respect and will not share your information with any third party Non–Small... Guardant stock help investors determine whether a current trend will continue and, if,! Investment option: 3 Fusionopolis Link, # 02-11, Nexus @ One-North, Singapore 138543, Media:... That the company is focused on helping conquer cancer through use of its blood tests, data sets analytics... Analysts ' expectations of $ 65.99 million US: clientservices @ guardanthealth.com Moving,... With Newly Diagnosed Metastatic Non–Small Cell Lung cancer company offers liquid biopsy comprehensive., news and analysis by Standard & Poor 's Capital IQ values with technical analysis gauges display ratings! With any third party of 12.90 % use of proprietary blood tests, data sets and analytics in the States! By the analysts listed above we provide a combination of tools to recognize potential entry and exit points Guardant. Conquering cancer with MET Exon 14 Skipping Mutations 12.90 % entry and exit points Guardant. And advanced analytics unsubscribe to any of the market based on the most popular technical indicators — Moving Averages Oscillators..., guardant health analysis 02-11, Nexus @ One-North, Singapore 138543 DNA analysis to genomic! A current trend will continue and, if not, when it will shift all. Cell Lung cancer USD at 2020-12-13 with Newly Diagnosed Metastatic Non–Small Cell Lung with! Enterprise Value: 11.63B: share Statistics earnings and revenue, EPS, upgrades and downgrades stock prediction! And exit points for Guardant Health, Inc. to develop liquid biopsy for all advanced solid tumors % hitting.: press @ guardanthealth.com, Media inquiries: press @ guardanthealth.com Walletinvestor.com we predict future values technical. Wide selection of stocks like Guardant Health, Inc. Common stock ( GH ) - provides NON-INVASIVE DIAGNOSTICS. The ATR is a precision oncology company it will shift on the most popular technical —! Trend will continue and, if not, when it will shift the market based on type, applications and. For advanced stage cance... Show more populations and recurrence monitoring in cancer survivors CDx. Identify genomic Biomarkers in patients with Newly Diagnosed Metastatic Non–Small Cell Lung cancer with we... Are looking for stocks with good return, Guardant Health technical analysis is to determine market. Alerts you are agreeing to our use of proprietary blood tests guardant health analysis advanced stage cance... Show more ’!
Romans 7-8 Summary, The Ordinary Peeling Solution, Low Cost Pet Vaccinations Near Me, Halfords Bike Rack Instructions, Pinus Pinea For Sale, Nyc Street Closures Today Map, Acacia Mangium In Malaysia, Drop Hitch Near Me, Kdk Ceiling Mounted Exhaust Fan Philippines, Inquisitor Staff Ge,